Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer

Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer Key PointsQuestionCan a genomic biomarker estimate the risk of prostate cancer clinical end points in men who received salvage radiation for rising prostate-specific antigen levels after surgery? FindingsIn this ancillary study of 352 men randomized to placebo or hormone therapy in the NRG/RTOG 9601 clinical trial of salvage radiation, the Decipher genomic classifier was independently associated with the risk of metastasis, prostate cancer–specific mortality, and overall survival. MeaningThese findings suggest that the Decipher genomic classifier is a promising biomarker to risk stratify men to better enable hormone therapy treatment decisions for biochemical recurrence of their prostate cancer after surgery. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Loading next page...
 
/lp/american-medical-association/validation-of-a-22-gene-genomic-classifier-in-patients-with-recurrent-2r0VnyRRhw
Publisher
American Medical Association
Copyright
Copyright 2021 Feng FY et al. JAMA Oncology.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2020.7671
Publisher site
See Article on Publisher Site

Abstract

Key PointsQuestionCan a genomic biomarker estimate the risk of prostate cancer clinical end points in men who received salvage radiation for rising prostate-specific antigen levels after surgery? FindingsIn this ancillary study of 352 men randomized to placebo or hormone therapy in the NRG/RTOG 9601 clinical trial of salvage radiation, the Decipher genomic classifier was independently associated with the risk of metastasis, prostate cancer–specific mortality, and overall survival. MeaningThese findings suggest that the Decipher genomic classifier is a promising biomarker to risk stratify men to better enable hormone therapy treatment decisions for biochemical recurrence of their prostate cancer after surgery.

Journal

JAMA OncologyAmerican Medical Association

Published: Apr 11, 2021

References